For: | Zori AG, Yang D, Draganov PV, Cabrera R. Advances in the management of cholangiocarcinoma. World J Hepatol 2021; 13(9): 1003-1018 [PMID: 34630871 DOI: 10.4254/wjh.v13.i9.1003] |
---|---|
URL: | https://www.wjgnet.com/1948-5190/full/v13/i9/1003.htm |
Number | Citing Articles |
1 |
Menglu Dai, Xiaohui Zhao, Aijun Yu, Luwen Zhao, Qingmin Kang, Shujun Yan, Xuejun Zhang, Jinlong Liu. Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients with Bile Duct Cancer: A Meta-Analysis. Nutrition and Cancer 2024; 76(10): 914 doi: 10.1080/01635581.2022.2104876
|
2 |
Zheng Yin, Qi Liu, Ying Gao, Ruizhi Wang, Yunling Qi, Dong Wang, Lianzhou Chen, Xiaoyu Yin, Meifang He, Wen Li. GOLPH3 promotes tumor malignancy via inhibition of ferroptosis by upregulating SLC7A11 in cholangiocarcinoma. Molecular Carcinogenesis 2024; 63(5): 912 doi: 10.1002/mc.23697
|
3 |
Zijiao Yang, Xia Jiang. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02754-y
|
4 |
Zhiwen Zhu, Yang Zheng, Huijuan He, Liangfang Yang, Jiaqi Yang, Mingyi Li, Wei Dai, Haili Huang. FBXO31 sensitizes cancer stem cells‐like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma. Liver International 2022; 42(12): 2871 doi: 10.1111/liv.15462
|
5 |
Jon M. Harrison, Brendan C. Visser. Cholangiocarcinoma. Surgical Clinics of North America 2024; 104(6): 1281 doi: 10.1016/j.suc.2024.04.003
|
6 |
Lei Zhang, Donglai Ma, Fujun Li, Gongcai Qiu, Dongsheng Sun, Zhaolin Zeng. Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.871281
|
7 |
Shizhuan Huang, Haotian Wu, Feng Luo, Bin Zhang, Tianwei Li, Zongrui Yang, Bixuan Ren, Wenze Yin, Dehai Wu, Sheng Tai. Exploring the role of mast cells in the progression of liver disease. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.964887
|
8 |
Chao Wang, Pingcuo Ciren, Awang Danzeng, Yong Li, Cheng-Long Zeng, Zhi-Wei Zhang, Zhi-Yong Huang, Yi-Fa Chen, Wan-Guang Zhang, Bi-Xiang Zhang, Bin-Hao Zhang, Xiao-Ping Chen, Shuang-zheng Jia. Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/4446243
|
9 |
Dominika Jamioł-Milc, Anna Gudan, Karolina Kaźmierczak-Siedlecka, Joanna Hołowko-Ziółek, Dominika Maciejewska-Markiewicz, Katarzyna Janda-Milczarek, Ewa Stachowska. Nutritional Support for Liver Diseases. Nutrients 2023; 15(16): 3640 doi: 10.3390/nu15163640
|
10 |
Maryam Makki, Malak Bentaleb, Mohammed Abdulrahman, Amal Abdulla Suhool, Salem Al Harthi, Marcelo AF Ribeiro Jr. Current interventional options for palliative care for patients with advanced-stage cholangiocarcinoma. World Journal of Clinical Oncology 2024; 15(3): 381-390 doi: 10.5306/wjco.v15.i3.381
|
11 |
Uchenna E Okpete, Haewon Byeon. Elevated <i>ETV4</i> expression in cholangiocarcinoma is linked to poor prognosis and may guide targeted therapies. World Journal of Gastrointestinal Oncology 2024; 16(11): 4528-4531 doi: 10.4251/wjgo.v16.i11.4528
|